Pro-Resolving Mediators: What They Are and How They Work

Pro-resolving mediators are a group of molecules your body makes from fatty acids to actively shut down inflammation once it has done its job. For decades, scientists assumed inflammation simply faded on its own when the threat was gone. That assumption turned out to be wrong. Research over the past two decades has revealed that resolution is a biochemically active process, driven by specific lipid molecules that signal immune cells to stop fighting, clean up the battlefield, and begin tissue repair. These molecules, collectively called specialized pro-resolving mediators (SPMs), include families known as lipoxins, resolvins, protectins, and maresins, and they are now recognized as central players in conditions ranging from heart disease to chronic pain.

Resolution Is Not Inflammation Running Out of Steam

The older view of inflammation treated it like a fire that simply burns out when it runs out of fuel. Remove the infection or injury, the thinking went, and the swelling and redness will fade passively. This assumption shaped medical thinking for a long time, and it is part of why most anti-inflammatory drugs focus on blocking the onset of inflammation rather than promoting its resolution. The discovery of SPMs overturned that framework. Within inflamed tissues that are healing normally, the body switches on entirely new biochemical pathways that produce mediators whose sole purpose is to wind down the immune response and restore normal tissue function.¹ This “active resolution” model has major implications: if the body has a built-in off switch for inflammation, then chronic inflammatory diseases might partly result from that switch failing rather than from inflammation being too strong.

The Four Main Families and Where They Come From

SPMs are not a single molecule but a large superfamily grouped into four main families based on their chemical structures and the fatty acids they derive from.

Lipoxins: Made from arachidonic acid, an omega-6 fatty acid. Lipoxins were the first pro-resolving mediators discovered and remain the best-studied members of the omega-6 branch.
Resolvins: Split into E-series (from EPA, eicosapentaenoic acid) and D-series (from DHA, docosahexaenoic acid), both omega-3 fatty acids. Resolvins are named for their role in the resolution of inflammation.
Protectins: Also derived from DHA. The brain-specific form, neuroprotectin D1, has drawn particular interest for neurodegenerative conditions.
Maresins: Produced from DHA primarily by macrophages, the large immune cells responsible for debris cleanup. The name stands for “macrophage mediators in resolving inflammation.”

All four families share certain actions: they limit the flood of neutrophils (the first-responder immune cells) into inflamed tissue, they reduce the production of inflammatory signaling molecules, and they stimulate macrophages to engulf dead cells and debris.² But each family also has distinct features. Resolvins and protectins, for instance, have been shown to enhance bacterial killing alongside their anti-inflammatory effects, which matters because you do not want to suppress inflammation so completely that pathogens survive.³

A key detail that separates SPMs from traditional anti-inflammatory drugs: the precursors for three of the four families are omega-3 essential fatty acids (EPA and DHA), while lipoxins come from the omega-6 fatty acid arachidonic acid.⁴ Additional SPMs derived from a third omega-3 fatty acid, docosapentaenoic acid (DPA), have also been identified, broadening the family further.⁵

How SPMs Work at the Cellular Level

Inflammation begins with neutrophils rushing to the site of injury or infection. They are effective killers, but they also cause collateral damage. One of the first things SPMs do is tell the body to stop sending more neutrophils. They counteract the chemical signals that recruit these cells, effectively closing the gate on the inflammatory influx.

The next step is cleanup. When neutrophils finish their work, they undergo a controlled form of cell death. Left uncleared, these dead cells would spill their toxic contents and perpetuate tissue damage. SPMs stimulate macrophages to engulf and digest these dead neutrophils, a process called efferocytosis. This cleanup step is not merely housekeeping. When macrophages perform efferocytosis, the process itself triggers them to produce more SPMs, creating a positive feedback loop that accelerates resolution.⁶ Even tiny particles shed by dying neutrophils contribute fatty acid precursors that macrophages convert into SPMs during the cleanup process.

SPMs carry out these actions by binding to specific receptors on the surface of immune cells. These receptor-driven pathways do more than simply quiet inflammation. They also guide the trafficking of immune cells, shift the balance of signaling molecules from inflammatory to repair-oriented, and promote tissue regeneration.⁷ Recent research on one DHA-derived mediator showed it operated at nanomolar concentrations, meaning vanishingly small amounts were enough to limit neutrophil infiltration, reduce neutrophil adhesion to blood vessel walls, protect endothelial cells from aging-related damage, and boost macrophage efferocytosis.⁸ The potency at such low concentrations is part of what makes SPMs attractive as potential therapeutics.

Unstable Plaques and Heart Disease

Atherosclerosis, the buildup of fatty plaques in arteries, is fundamentally an inflammatory disease. What determines whether a plaque causes a heart attack is not just its size but its stability. Vulnerable plaques have thin fibrous caps, large dead-cell cores, and heavy oxidative stress. Stable plaques, by contrast, have thick protective caps and less internal damage. Research on human carotid arteries found that vulnerable plaque regions had a pronounced imbalance: far fewer SPMs relative to pro-inflammatory molecules like leukotriene B4 compared to stable regions of the same artery.⁹

The same pattern showed up in mouse models of atherosclerosis fed high-fat diets: advanced plaques had a skewed ratio of SPMs to inflammatory lipids compared with early-stage lesions.¹⁰ When researchers gave resolvin D1 to these mice during plaque progression, it restored the SPM-to-leukotriene ratio toward what is seen in less advanced lesions. The treated plaques showed less oxidative stress, less cell death inside the plaque core, better clearance of dead cells, and thicker fibrous caps.⁹ This does not mean SPMs will prevent heart attacks in humans, but it establishes a clear mechanistic link between failed resolution and the kind of plaques that rupture and cause clinical events.

Protection in the Brain

The brain is rich in DHA, which makes it a natural site for DHA-derived SPMs. One of the most studied is neuroprotectin D1 (NPD1). In experimental stroke models, NPD1 reduced the infiltration of immune cells into damaged brain tissue, dampened inflammatory signaling, and shrank the size of the resulting brain injury.¹¹

In Alzheimer’s disease research, NPD1 has drawn attention because of its effects on amyloid-beta, the protein fragment that accumulates in Alzheimer’s brains. Lab studies using human nerve cells showed that NPD1 counteracted the cell-killing effects of toxic amyloid-beta fragments, improving cell survival and reducing markers of programmed cell death.¹² NPD1 also appears to suppress the production of amyloid-beta itself and to switch on genes involved in cell survival and neuroprotection.¹¹ These are lab and animal findings, so the leap to clinical treatment is still large, but they illustrate that the brain has its own built-in resolution circuitry that may falter in neurodegenerative conditions.

A Different Approach to Pain

Chronic pain and inflammation are closely linked, and the standard approach to managing inflammatory pain, nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids, comes with well-known side effects and limitations. SPMs offer a conceptually different strategy: instead of blocking the inflammatory signals that cause pain, they promote the resolution process that should naturally bring pain to an end.

Several SPMs, including resolvin D1, resolvin E1, and maresin 1, have been shown in animal studies to reduce pain by suppressing inflammatory signaling molecules, interacting with ion channels involved in pain sensation, and helping immune cells resolve the underlying inflammation.¹³ This has been tested in specific pain scenarios. In mice with nerve-injury-induced neuropathic pain, resolvin E1 injected into the spinal canal reduced both pain behavior and the immune reaction in the spinal cord. Resolvins D1 and D2 reversed pain caused by paclitaxel, a common chemotherapy drug, which is relevant because chemotherapy-induced nerve pain has no FDA-approved treatment and often forces patients to reduce or stop cancer therapy.¹⁴

Diet, Fish Oil, and SPM Levels in Your Blood

Because the main precursors for resolvins, protectins, and maresins are EPA and DHA, a natural question is whether eating more omega-3-rich foods or taking supplements actually raises SPM levels in the body. The evidence says yes, though the size of the effect depends on your starting point.

A randomized, placebo-controlled trial found that enriched marine oil supplements increased circulating SPM concentrations in a time- and dose-dependent manner, and also shifted how immune cells in the blood behaved, reprogramming them toward a more resolution-oriented profile.¹⁵ A separate year-long trial confirmed the pattern: participants taking omega-3 fatty acids saw reductions in pro-inflammatory mediators and increases in pro-resolving ones, including resolvin D1 and resolvin D4. The changes were largest in people who ate little fish at baseline, suggesting that those already getting ample omega-3s from diet had less room for improvement.¹⁶

In patients with peripheral artery disease taking fish oil supplements, doubling the omega-3 index (a measure of EPA and DHA in red blood cell membranes) correlated with roughly two- to fourfold increases in several SPM pathway markers.¹⁷ These are intermediate biomarkers, not clinical endpoints, so they do not prove that supplements prevent disease. But they do establish that dietary omega-3 intake feeds directly into the body’s SPM-producing machinery.

Exercise Triggers Its Own Resolution Program

Here is something that surprises many people: a bout of intense exercise triggers an inflammatory response, and the body’s resolution of that response follows the same SPM pathways seen in infection or injury. After unaccustomed resistance exercise in humans, researchers detected elevated blood levels of lipoxins, resolvins, and protectins during the recovery period. The acute inflammatory signals produced by the exercise were mechanistically linked to switching on the resolution program, meaning the inflammation itself helped activate the off switch.¹⁸

This finding has a practical twist. Many people take NSAIDs like ibuprofen before or after exercise to manage soreness. But if exercise-induced inflammation is what triggers the SPM-driven resolution and repair program, suppressing that initial inflammation with drugs could interfere with the very recovery process the drugs are supposedly supporting. The same study examined ibuprofen’s effects in this context, raising questions about whether routine NSAID use around exercise disrupts a beneficial resolution pathway. It echoes a broader concern in the SPM field: blocking inflammation is not the same thing as resolving it, and the two strategies may have very different downstream consequences for tissue repair.

Aging and Declining Resolution Capacity

Older adults are more prone to chronic, low-grade inflammation, sometimes called “inflammaging.” Part of the explanation may be that the body’s ability to produce SPMs declines with age. A study comparing aged and young mice found that old animals had lower baseline levels of several SPMs in skeletal muscle, including maresin 1, resolvin E3, and an oxidized form of resolvin D1. When researchers then induced muscle injury, the aged mice showed greater inflammation, poorer muscle fiber regeneration, and slower recovery of strength, all linked to inadequate local SPM production.¹⁹

The researchers noted an additional wrinkle: NSAIDs, the standard treatment for pain and inflammation in elderly patients, may improve symptoms in the short term but can negatively affect tissue regeneration. SPMs, by contrast, promoted recovery of muscle function without those regenerative side effects, at least in the animal models. If this holds in humans, SPMs or their analogs could become an appealing alternative for managing inflammation-related problems in aging populations.

Why SPMs Are So Hard to Measure

One reason SPM research has been contentious is that these molecules are extraordinarily difficult to measure. They exist in tissues at picogram-level concentrations, vanishingly tiny amounts that push analytical instruments to their limits. Modern measurement relies on liquid chromatography coupled with tandem mass spectrometry, and even small differences in laboratory technique can yield different results. One methodological study reported working at detection limits of a fraction of a picogram on column for the lowest-abundance SPMs, requiring careful optimization of sample preparation, purification, and instrument focusing to get reliable numbers.²⁰

An additional complication is that SPMs have very similar chemical structures to one another. Resolvins, protectins, and lipoxins each have multiple stereoisomers, mirror-image molecules that behave differently in the body but look almost identical to an instrument. Separating the biologically active form from inactive isomers requires chemically pure reference standards made through total organic synthesis and carefully tuned chromatographic methods that can distinguish molecules differing only in the orientation of a single chemical bond.²¹ These measurement difficulties have fueled debates within the field about whether SPMs circulate in blood at biologically meaningful levels or act purely at local tissue sites. The debate is less about whether SPMs exist and work, where the evidence is strong, and more about the exact concentrations reported in different labs and tissues.

From Natural Molecules to Drug Candidates

Natural SPMs are potent but fragile. Once released in tissue, they are rapidly broken down by enzymes, which limits how long they act. This fast metabolism is a feature in normal biology, where you want resolution to be tightly controlled, but it is a problem if you want to give SPMs as a drug. A pill or injection of resolvin D2 would be chewed up by the body before it had a sustained effect.

One approach to solving this is to build synthetic analogs that mimic the shape and receptor-binding properties of natural SPMs but resist enzymatic breakdown. Researchers recently created a modified version of 17R-resolvin D2, called benzo-17R-RvD2, by incorporating a benzene ring into the molecule’s backbone. The ring makes the molecule more chemically stable against the enzymes that normally inactivate it, while preserving its ability to act as a resolution agonist.²² This kind of medicinal chemistry work is still in early stages. No SPM-based drug has reached the market yet, and moving from synthetic analogs active in lab settings to a safe, effective medicine for humans remains a long road. But the concept is appealing because it would represent a fundamentally different kind of anti-inflammatory therapy: one that helps the body finish the job rather than just blocking it from starting.

Aspirin and an Unexpected Connection

One of the more interesting footnotes in SPM biology involves aspirin. At low doses, aspirin modifies the enzyme cyclooxygenase-2 (COX-2) in a way that diverts its activity. Instead of producing the usual pro-inflammatory prostaglandins, the aspirin-modified enzyme generates a different set of products, including a class of SPMs called aspirin-triggered lipoxins and aspirin-triggered resolvins. These aspirin-triggered forms have the same pro-resolving actions as their naturally occurring counterparts but are somewhat more resistant to breakdown. This pathway has been proposed as one reason aspirin has anti-inflammatory benefits beyond simple prostaglandin suppression, and it connects SPM biology to one of the oldest and most widely used drugs in the world. Statins, the cholesterol-lowering drugs, have also been linked to increased production of certain SPMs, adding another layer to the story of how existing medications might already be tapping into resolution pathways without anyone originally realizing it.²³

The 5-lipoxygenase enzyme illustrates the dual nature of these biochemical pathways especially well. The same enzyme that produces pro-inflammatory leukotrienes in one context generates anti-inflammatory resolvin E2 from an EPA-derived precursor in another.²⁴ Whether the enzyme makes a pro-inflammatory or a pro-resolving product depends on timing, on which fatty acid substrates are available, and on the cellular context. This is part of why blunt suppression of inflammatory enzymes with drugs can have unintended consequences: you might be shutting down not just the alarm, but the repair crew that follows.